Repurposing as a strategy for the discovery of new anti-leishmanials: the-state-of-the-art

REBECCA L. CHARLTON1,2, BARTIRA ROSSI-BERGMANN2, PAUL W. DENNY3 and PATRICK G. STEEL1*

1 Department of Chemistry, University Science Laboratories, South Road, Durham DH1 3LE, UK
2 Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Ilha do Fundão, CEP 21 949-900 Rio de Janeiro, RJ, Brazil
3 Department of Biosciences, University Science Laboratories, South Road, Durham DH1 3LE, UK

(Received 28 February 2017; revised 23 May 2017; accepted 25 May 2017; first published online 14 August 2017)

SUMMARY

Leishmaniasis is a vector-borne neglected tropical disease caused by protozoan parasites of the genus Leishmania for which there is a paucity of effective viable non-toxic drugs. There are 1·3 million new cases each year causing considerable socioeconomic hardship, best measured in 2·4 million disability adjusted life years, with greatest impact on the poorest communities, which means that desperately needed new antileishmanial treatments have to be both affordable and accessible. Established medicines with cheaper and faster development times may hold the cure for this neglected tropical disease. This concept of using old drugs for new diseases may not be novel but, with the ambitious target of controlling or eradicating tropical diseases by 2020, this strategy is still an important one. In this review, we will explore the current state-of-the-art of drug repurposing strategies in the search for new treatments for leishmaniasis.

Key words: leishmaniasis, repurposing, repositioning, drug discovery.

INTRODUCTION: DRUG REPOSITIONING

The introduction of a new drug from initial concept to public release is a slow expensive process. Developing a new chemical entity (NCE) drug and delivering it to market, de novo drug discovery (Fig. 1), is estimated to take 10–17 years and cost ~$1·8 billion (Paul et al. 2010). Moreover, the probability of success is lower than 10% and the costs of late stage failures in this process are significant and are accounted for in the high cost of patented drugs. Consequently, the discovery of new drugs for leishmaniasis, and other neglected tropical diseases, for which the average patient suffering from visceral leishmaniasis (VL) exists on an income of less than $2 per day (WHO, 2002), is simply not a commercially viable operation for pharmaceutical companies without significant cross-subsidy.

Alternative strategies are therefore needed and the process of drug repositioning or repurposing, where new applications for existing drugs or drug candidates are discovered and refined, has become increasingly common (Ashburn and Thor, 2004; Aubé, 2012; Oprea and Mestres, 2012; Andrews et al. 2014; Klug et al. 2016; Jain and Sharma, 2017). When using a drug repositioning strategy several development phases necessary to develop NCE drugs can be bypassed or considerably shortened (Fig. 1) because candidates will have passed various checkpoints and information is available about their pharmacokinetic and safety profiles. Reflecting this, the process of finding new uses for drugs outside their original indication is becoming increasingly successful as more companies are screening their libraries for repurposing candidates. Figure 2 illustrates two examples of approved drugs possessing optimum properties for their new indication. However, it should be noted that these cases are relatively rare and some development work is still commonly required. Moreover, whilst serendipity (phenotypic screening) can play a sizeable role in identifying repurposed drugs, it is important to establish the molecular connection between old drugs and new targets as this information aids the development of the new therapeutics. Despite these caveats drug repositioning can reduce time, cost and risk, and is a particularly attractive approach for neglected tropical diseases where new medications are needed urgently to treat the poorest of people. In this review, we will focus on the neglected tropical disease, leishmaniasis, and how repositioning strategies have shown potential to enable the discovery of new medicines for this disease.

LEISHMANIASIS

Leishmaniasis is an important vector borne ‘Neglected Tropical Disease’ caused by protozoan parasites of the genus Leishmania (Roberts, 2006). With over 350 million people world wide considered...
at risk, 12 million people currently infected (Kedzierski, 2010), one million new cases reported annually, more than 30,000 deaths each year (WHO, 2016) and an economic cost that can be best estimated in terms of 2·4 million disability adjusted life years, the health challenge is only surpassed amongst parasitic diseases by malaria, schistosomiasis and lymphatic filariasis (Davies et al. 2003; Bern et al. 2008). Consequently, leishmaniasis has been classified by the World Health Organization as Category I: emerging or uncontrolled diseases. In particular, the spread and severity of infection is exacerbated by its status as an important co-infection of AIDS patients and the overlap in prevalence of HIV and Leishmania spp. (Alvar et al. 2008). The disease is endemic in 98 countries across five continents and has strong links with poverty, principally affecting low income regions of Africa, Asia and Latin America (Alvar et al. 2012). However, the impact of the disease is spreading and, reflecting population movements and climate change, leishmaniasis has also been recorded with growing frequency in Southern Europe (Gradoni, 2013).

Leishmaniasis is transmitted through the bite of infected female phlebotomine sandflies. Subsequently, in the mammalian host, flagellated promastigote Leishmania spp. are taken up by macrophages where they transform into the non-flagellated amastigote form, proliferate and cause disease. Infected macrophages can then be taken up by the insect vector during a second blood meal, the parasite then transforms back to the promastigote form and the cycle is perpetuated. Importantly, many Leishmania spp. can infect multiple mammalian species leading to animal reservoirs for human infection, most notably in canines (Solano-Gallego et al. 2011).

Human disease is caused by 20 of the 31 parasite species that infect mammals with the different species leading to different clinical manifestations (Akhoundi et al. 2016). Depending on parasite tropism for skin or visceral macrophages, and host immune status, clinical forms range from localized cutaneous leishmaniasis (CL), diffuse CL, disseminated CL, mucosal CL, to visceral leishmaniasis (VL). The most common form of the disease is CL which, although not fatal, leads to slow growing skin lesions, which leave permanent scars and in some cases cause serious disability. Mucocutaneous leishmaniasis is the most disfiguring form and causes destruction of soft tissue in the nose, mouth.

---

**Fig. 1.** Drug discovery and repositioning pathways (adapted from Guha et al. 2015).

**Fig. 2.** Examples of old drugs directly repositioned as treatments for new diseases and dysfunctions.

---

**De novo Drug Discovery and Development: 10 to 17 years**

<table>
<thead>
<tr>
<th>Phase</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Target Discovery</td>
<td>2-3 years</td>
</tr>
<tr>
<td>Screening &amp; Lead Discovery</td>
<td>0.5-1 years</td>
</tr>
<tr>
<td>Lead Optimisation</td>
<td>1-3 years</td>
</tr>
<tr>
<td>Preclinical Development</td>
<td>1-2 years</td>
</tr>
<tr>
<td>Clinical Trials</td>
<td>5-6 years</td>
</tr>
<tr>
<td>Licensing</td>
<td>1-2 years</td>
</tr>
</tbody>
</table>

**Drug Repositioning: 3 to 12 years**

<table>
<thead>
<tr>
<th>Phase</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Compound Identification</td>
<td>1-1.5 years</td>
</tr>
<tr>
<td>Compound Acquisition</td>
<td>0-1.5 years</td>
</tr>
<tr>
<td>Preclinical Development</td>
<td>0-1 years</td>
</tr>
<tr>
<td>Clinical Trials</td>
<td>1-6 years</td>
</tr>
<tr>
<td>Licensing</td>
<td>1-2 years</td>
</tr>
</tbody>
</table>
and throat. In contrast, VL is the most severe form of the disease as it affects the vital organs of the body and is fatal if left untreated (CDC, 2016).

Treatment of leishmaniasis is challenging and there are currently no vaccines or prophylactic drugs to prevent human infection. For over 70 years, the mainstay of antileishmanial therapy has been pentavalent antimonials (Pentostam and Glucantime) which are administered by slow intravenous or intramuscular injections (Kedzierski et al. 2009). The mode of action is not fully understood but one possibility involves the biological reduction of Sb(V) to Sb(III) by the parasite or by infected host cells to create antileishmanial activity (Shaked-Mishan et al. 2001; Krauth-Siegel & Comini 2008). Unfortunately, antimonials are also toxic (Sundar and Chakravarty, 2010b) and reports of resistance are becoming increasingly common. For example, a study of the efficacy of Pentostam in, in North Bihar, India, revealed that only 36% of patients could be cured when treated with a dose of 20 mg kg⁻¹ for 30 days (Croft et al. 2006).

For the past seven decades, amphotericin B (AmpB) and pentamidine have been used in cases of antimonial failure (Kedzierski et al. 2009). Pentamidine is an antimicrobial medication that was commonly used as a second line, parenteral, treatment for leishmaniasis in the case of antimonial failure. The primary mode of action of pentamidine in kinetoplastids is not well understood but there is some evidence that it inhibits the active transport system and disrupts the mitochondrial membrane potential. However, pentamidine has lower efficacy than amphotericin B (Lockwood and Moore, 2010) and this, coupled with severe toxicity, have resulted in a gradual decline in its use (No, 2016).

The antifungal drug AmpB, first isolated in 1955, was reported to have antileishmanial activity in the early 1960s. AmpB binds to ergosterol, forming pores in the membrane, which leads to the death of the parasite (Kamiński, 2014). Whilst severe side effects limited its use, liposomal formulations that circumvent these problems have been developed. However, a course of L-AmpB still requires parenteral administration and, without extensive subsidy is expensive (up to $3000 per course). This makes L-AmpB inaccessible to most patients who live in the poorest, least developed regions. In comparison, an equivalent course of pentavalent antimonials costs between $150 and $198 (de Menezes et al. 2015). Despite this, L-AmpB is now often preferred over Pentostam for VL because it is less toxic and there are fewer reports of parasitic resistance (Croft et al. 2006; Sundar and Singh, 2016).

Along with L-AmpB, paromomycin and miltefosine are now approved drugs for VL (Sundar and Chakravarty, 2015). Paromomycin is an antibiotic and a relatively new therapy for the parenteral treatment of VL in India. It has been shown to be effective and relatively cheap first-line treatment with low toxicity, requiring a course of 15 mg kg⁻¹ for 21 days (Musa et al. 2010; No, 2016). The mechanism of action is not fully understood but it is thought to inhibit protein synthesis (Fernández et al. 2011). As with the other treatments there are drawbacks, the drug is administered by injection (Sundar et al. 2007) and shows poor efficacy in some regions in Africa (Hailu et al. 2010).

As discussed above, these current medications all involve prolonged parenteral administration, which leads to many complications, including poor patient compliance, blood-borne disease from unsanitary conditions and the need for medical facilities. Therefore, in the past two decades there has been a focus on developing new oral therapies. In 2002 miltefosine, originally developed as an anticancer agent, was introduced as the first oral antileishmanial agent (Soto and Berman, 2006). The primary mechanism of action is poorly understood, although the drug is thought to involve disruption of ether-phospholipid metabolism, glycosylphosphatidylinositol anchor biosynthesis and signal transduction within the parasite (No, 2016). Miltefosine efficacy against both VL and CL has been reported and, in 2014, the US Food and Drug Administration approved the drug for all forms of leishmaniasis (Dorlo et al. 2012). However, this oral therapy does have limitations, including high costs and teratogenic effects. Moreover, the long-term effectiveness of miltefosine is questionable, with reports of VL relapses in Nepalese patients treated with this drug. In addition, miltefosine resistance is readily induced in Leishmania donovani in vitro (Seifert et al. 2003).

In conclusion, all current treatments (Fig. 3) have serious limitations such as high cost, route of administration, severe toxic side effects and increasing drug resistance. Currently, there are some new therapies under clinical investigation as monotherapies or in combination with existing antileishmanials (Bahamdan et al. 1997; Alrajhi et al. 2002; Momeni et al. 2002; Machado et al. 2007; Sundar et al. 2011; ClinicalTrials.gov, 2016). These include paromomycin topical cream, currently in phase 3 trials as a treatment for CL, and sitamaquine in phase 2 to treat VL.

Repositioning of drugs targeting Leishmaniasis

Significantly, as noted above in the Introduction, many of the existing therapies for leishmaniasis are licensed or were initially intended for other illnesses. For example, Amphotericin B is an antifungal drug, paromomycin is an aminoglycoside antibiotic used to treat intestinal infections, and miltefosine was originally developed as an anticancer agent.
This section will review drugs for different disease states; cancer, microbial infection, depression, allergies and others; that have shown potential to be repurposed as new antileishmanial therapies, and discuss their putative parasitic drug targets.

It should be noted that many natural products often used in traditional medicines have antileishmanial activity, including vast numbers of different alkaloids (Mishra et al. 2009a, b), flavonoids (Mittra et al. 2000; da Silva et al. 2012) chalcones (Chen et al. 1994; Boeck et al. 2006; Aponte et al. 2010; de Mello et al. 2014) and terpenoids (Rosa et al. 2003; Torres-Santos et al. 2004; Arruda et al. 2005; Mazoir et al. 2011). These compounds have been discussed extensively in previous literature (Mishra et al. 2009a, b; Schmidt et al. 2012; Singh et al. 2014a) however, they are structurally complex molecules, often affecting multiple targets and possess properties that make them unlikely to be orally active drugs. As such the greatest potential of natural products is for the identification of novel targets required to underpin target-based drug discovery and not as starting points for a repositioning strategy and therefore they will not be discussed further in this review.

Anticancer drugs

Both cancerous cells and Leishmania spp. have the ability to proliferate in a host organism for prolonged periods of time and some enzymes targeted by anticancer therapies can also be used in the development of antileishmanials (Fig. 4, Table 1) (Klinkert and Heussler, 2006; Uliana and Barcinski, 2009).

Kinases have long been recognized as a major target in oncology and this has spawned a number...
of efforts to repurpose a range of kinase inhibitors for leishmaniasis. For example, miltefosine 8 is the first, and still the only, oral drug in the treatment of VL but was originally developed as a treatment for breast cancer. Like many anticancer drugs, miltefosine 8 induces apoptosis through kinase inhibition. In this case the PI3K/Akt/PkB pathway is targeted and it has been reported that inhibition of this pathway may influence the susceptibility of host cell to Leishmania infection (Dorlo et al. 2012).

The genomes of trypanosomatids encode at least 12 proteins belonging to the PI3K protein superfamily, many of which are unique to the parasites. The Target of Rapamycin (TOR) kinase is a member of the PI3K-related kinase (PKK) subfamily and has a central role in fundamental processes such as growth, cell shape and autophagy. Trypanosomatids possess four distinct genes belonging to the TOR family whereas mammals only possess one mTOR protein. On this basis, a targeted set of eight known mTOR inhibitors with varied potencies and selectivity for mTOR/PI3K were screened against *Trypanosoma brucei*, *Trypanosoma cruzi*, cutaneous *Leishmania major* and visceral *L. donovani*.

From these data, the mTor/PI3K inhibitor, Dactolisib 10, was identified as being the most active against all the species tested and therefore was tested in animal models of *T. brucei rhodesiense*, *T. cruzi* and

**Fig. 4.** Treatments for cancer that could be repurposed as antileishmanials.
L. major. Unfortunately, no efficacy was observed against either T. cruzi or L. major; this may reflect the need for the drug to cross into the phagolysosomal compartment where the parasite resides. In contrast, and consistent with this hypothesis, Dactolisib significantly reduced the parasite burden and extended the survival of mice infected with T. brucei rhodesiense (Díaz-Gonzalez et al. 2011), a blood stream parasite. Although the exact mechanism of action has yet to be identified this investigation has demonstrated a potential target in the search for antitrypanosomal therapies.

Similar small scale focused screens against specific kinase targets have been conducted. For example, through exploring Aurora kinases, hesperidin 11 has been identified as a putative antileishmanial lead but host cell toxicity was observed when the compound was screened against the hepatic cancer cell line (Patel et al. 2014). Although, further structure-activity relationship (SAR) studies demonstrated that these inhibitors are not general toxins but can be modified to improve selectivity, useful antileishmanial selectivity was not obtained. More significantly, and consistent with other reports (De Muylder et al. 2011), there was no correlation between activity against promastigote and axenic amastigote with in this case the latter being the less sensitive form.

Whilst target-based screening is an attractive strategy, the need for a specific orthologous target protein may not be essential as many kinase inhibitors affect multiple proteins and simply the proven cellular accessibility of these compounds is a sufficient starting point. For example, whilst tyrosine kinases are not expressed in trypanosomatids, protein phosphorylation occurs in parasites and therefore kinase inhibitors may interact with other enzymes (Karaman et al. 2008; Peña et al. 2015). Reflecting this, in a screen of eleven tyrosine kinase inhibitors, sunitinib 12, sorafenib 13 and lapatinib 14 showed antileishmanial activity against intracellular L. donovani amastigotes (Sanderson et al. 2014). Control experiments confirmed that the leishmanial targets were unlikely to be the same as those found in mammalian cells and these kinase inhibitors showed a degree of selectivity against amastigotes compared with mammalian cells. In addition, an oral dose of sunitinib 12, sorafenib 13 and lapatinib 14 reduced liver parasite burden in mice infected with L. donovani. Whilst these screens identify new leads, the challenge for such studies is in the identification of the actual target to guide further optimization.

Kinas also as proved to be the most common predicted target from a set of 192 antileishmanial compounds identified from a high throughput phenotypic screen of 1-8 million compounds against representative kinetoplastid species, including L. donovani (Peña et al. 2015). However, since most of these compounds have no literature precedent this was not strictly a repurposing study, and further discussion is outside the scope of this review. Finally, an interesting, and somewhat different, study involving the repurposing of kinase inhibitors, was the use of imatinib 15 (Gleevec, another tyrosine kinase inhibitor used in the treatment of multiple cancers) to target the host macrophage Ab1 and Arg kinases believed to be involved in parasite entry to the cell. Mice infected with L. amazonensis were treated with oral imatinib, which resulted in smaller lesions that developed later and a reduction in parasite burden relative to controls. (Wetzel et al. 2012). Imatinib is a clinically approved drug with relatively benign side effects when compared with antileishmanials on the market. It would be of great benefit to further understand the cell entry pathway to provide new lines of therapy for leishmaniasis.

The approach of starting with inhibitors with known modes of action, for example against mammalian kinases, and screening for new antileishmanial activities for which orthologous protozoal targets can then be identified is an attractive concept. However, good levels of host parasite selectivity are required before any hits can be repurposed as antiparasitic therapeutics. This was nicely illustrated in a study exploring Lysine Deacetylases (KDAC) as putative antileishmanial drug targets. KDACs are one of the most studied epigenetic drug targets of humans (Wang et al. 2015) and inhibition of their activity is a validated strategy for cancer treatment (Patil et al. 2010). As with the kinases discussed above, Leishmania spp. have multiple genes encoding different HDACs isoenzymes some of which are essential to parasite survival (Patil et al. 2010). Whilst, the homology between kinetoplastid and mammalian KDACs is low (~40%) much higher levels of similarity are found in active site residues (Wang et al. 2015). Reflecting this only one compound, Hydroxamate 16, showed significant selectivity (~10-fold) between host cell and parasite and high (nanomolar) activity against axenic L. donovani amastigotes (Wang et al. 2015).

A final class of anticancer agents that have been shown to have potential as antileishmanials are the selective estrogen-receptor modulators, tamoxifen 17 and raloxifene 18, used to prevent and treat breast cancer. Both have been identified as potential candidates for leishmaniasis treatment with micromolar potency against intracellular Leishmania amazonensis amastigotes (Reimao et al. 2014; Doroodgar et al. 2016; Trinconi et al. 2016). The mechanism of action of tamoxifen 17 and raloxifene 18 is still unclear as estrogen responses have not been described in Leishmania spp. (Miguel et al. 2007, 2008). However, it has been postulated that tamoxifen 17 causes changes in parasite-membrane properties and disrupts sphingolipid synthesis (Trinconi et al. 2016), whereas raloxifene 18 is thought to damage the cell membrane and the mitochondrion
of the parasite (Reimao et al. 2014). Whilst the antileishmanial activity of these compounds has not necessarily been optimized, the proven safety profile of these repurposed drugs allows them to be considered as synergists in combination therapies to help combat growing concerns about the emergence of parasitic resistance. For instance, combination of tamoxifen and miltefosine in vitro and in vivo revealed no interaction between the two drugs and suggested that tamoxifen could slow the emergence of miltefosine resistance (Trinconi et al. 2016).

**Antimicrobial drugs**

An antimicrobial is any compound that kills or inhibits the growth of a microorganism; this can include bacteria, fungi, viruses and protozoa. Antimicrobial drugs that were originally licensed for other indications have already been repurposed as antileishmanials. For example, amphotericin B and pentamidine are antifungal medications and paromomycin is used to treat the parasitic diseases, cryptosporidiosis and amoebiasis. These examples of successfully repurposed antimicrobials as treatments for leishmaniasis have encouraged further investigation into the leishmanicidal activity of other antimicrobial drugs (Figs 5–8, Table 1).

**Antifungals**

As discussed above, the main use of amphotericin B is in the treatment of a wide range of fungal infections but is now also used to treat VL. Liposomal amphotericin B is the treatment of choice for immunocompetent patients in the Mediterranean region and the preferred drug for HIV/VL co-infection (Sundar and Chakravarty, 2010). AmpB functions by binding to ergosterol disrupting the plasma membrane. This is the major sterol of the fungal plasma membranes and there are other antifungal azoles, which inhibit C14α-demethylase, an essential enzyme in the biosynthesis of ergosterol. As the sterol biosynthesis pathway is conserved in Leishmania spp. parasites and is important for their survival (de Souza and Rodrigues, 2009), these antifungal azoles have the potential to be repurposed as antileishmanials. Fluconazole and terbinafine, two antifungal azoles, which have similar modes of actions, can be administered orally and possess low levels of toxicity; therefore, the use of these drugs as putative antileishmanials in clinical trials can be approached with some confidence. Oral fluconazole was shown to be a safe and useful drug for the treatment of CL caused by L. major (Alrajhi et al. 2002) and was reported to be more...
efficacious in higher doses after a phase 2 clinical study (Emad et al. 2011). However, a recent phase 3 clinical trial of the use of high dose fluconazole 19 in the treatment CL caused by L. braziliensis and L. guyanensis was terminated due to a low cure rate, suggesting species dependent activity (ClinicalTrials.gov, 2015a). The potential for terbinafine 20 as a new treatment for CL was first described in 1997. Significantly, at the dosage used, no patients reported any side effects. However, the efficacy appears lower than other azole antifungals notably, ketoconazole 21 and itraconazole 22, and further investigation is required to optimize the efficacy of the drug before it can be considered as an effective solution (Bahamdan et al. 1997). One method being investigated is using terbinafine 20 in combination therapies. For example, oral terbinafine 20 and cryotherapy has completed phase 1 of clinical trials for treatment of CL and results show a similar level of efficacy to glucantime 2 (Farajzadeh et al. 2015).
Positive results, coupled with attractive pharmacokinetic and safety profiles, with these antifungal azoles have encouraged the investigation of similar compounds. For example, itraconazole and posaconazole exhibit in vitro and in vivo activity against L. amazonensis, L. donovani and L. infantum. In addition, a separate study, econazole showed activity against L. infantum chagasi promastigotes and similar intramacrophage effectiveness to miltefosine (Mesquita et al., 2014).

**Antiparasitics**

A second source of antimicrobial compounds that have been exploited as antileishmanials are, not surprisingly, other antiparasitics. In one approach, a collection of 400 compounds obtained from Medicines for Malaria Venture (MMV) were screened for antileishmanial activity. Significantly, in contrast to many other such approaches, which use promastigote or axenic amastigotes, this study developed an assay using intracellular amastigotes, thus enabling screening against the most clinically relevant form of the parasite (Freitas-Junior et al., 2012). The results identified 14 antimalarial drugs that have antileishmanial activity. The compound of most interest was the anticancer drug, MMV666080, which, with an IC$_{50}$ of 15 nM, is more potent and also less toxic than amphotericin B. In addition, a series of substituted aminobenzimidazoles (26–28) were identified from this screen as active antileishmanials with IC$_{50}$ values ranging from 61 to 134 nM. A current focus for these compounds is to validate the results using in vivo models (Khraivesh et al., 2016).

A second set of studies has focused on the use of nitazoxanide, an oral drug used in the treatment of infectious diarrhoea caused by the protozoan parasites, Cryptosporidium parvum and Giardia lamblia. The lethal action of nitazoxanide against L. infantum involves upregulation of reactive oxygen species resulting in oxidative stress and parasite death (Mesquita et al., 2013). Nitazoxanide also displays activity against L. donovani and L. amazonensis (Zhang et al., 2010; Nava-Zuaño et al., 2014), with spleen and liver parasite load being reduced by 86% in L. donovani infected mice (Zhang et al., 2010). In addition, nitazoxanide demonstrates low cytotoxicity against mammalian VERO cell line and exhibits activity against Giardia intestinalis and Trichomonas vaginalis; therefore derivatives of nitazoxanide would generally be attractive starting points for new antiparasitic drugs (Nava-Zuaño et al., 2014).

Due to the closer taxonomy lineage, it would be expected that anti-trypanosomal drugs would be more likely repurposed to leishmaniasis than other antiparasitics. However, apart from pentamidine used to treat African trypanosomiasis caused by Trypanosoma gambiense, no other anti-trypanosomal drugs including those used to treat Chagas Disease are presently used against leishmaniasis.

Whilst nitroaromatics, such as nitazoxanide, are generally avoided in the pharmaceutical industry due to the known potential mutagenicity and carcinogenicity of the nitro group, recent research has revealed the potential of nitroaromatics to treat neglected parasitic diseases (Patterson and Wyllie, 2014). Reflecting this, another antiparasitic nitroaromatic compound, fexinidazole, is being explored as a potential treatment for leishmaniasis. Fexinidazole is in clinical trials for treating African trypanosomiasis (T. brucei) and Chagas disease (T. cruzi) where the mechanism of action is proposed to involve reductive activation of the nitro group by NADH-dependent bacterial-like nitroreductase. A study involving the overexpression of the leishmanial orthologue of the nitroreductase demonstrated that a similar mechanism occurs in Leishmania spp. Building on this fexinidazole and its two predominant in vitro metabolites (fexinidazole sulfoxide and sulfone) displayed excellent activity against L. donovani promastigotes and axenic amastigotes. However, fexinidazole was inactive against intracellular amastigotes whereas fexinidazole sulfoxide and sulfone remained potent against intracellular amastigotes (both EC$_{50}$ values equal to 5·3 µM). When progressed into a murine model infected with L. donovani a 98·4% suppression of infection was observed with a single daily dose of fexinidazole for 5 days (Wyllie et al., 2012). With this positive data, fexinidazole was progressed into clinical trials as a treatment for VL. In 2013, a phase II study tested fexinidazole on 14 patients suffering with VL and all patients showed clinical improvement during treatment. Unfortunately, treatment relapses were observed and thus the study was terminated in 2014 due to lack of efficacy (ClinicalTrials.gov, 2015b). However, fexinidazole is now being investigated as a combination therapy with miltefosine in Eastern Africa (DNDi, 2016).

Levamisole is a heterocyclic compound that is immunoregulatory and an effective anthelmintic agent (Goldstein, 1978). Since the 1970s it has been studied as a therapy for CL (Butler, 1978) and a more recent study compared the effects of levamisole and imidocarb, veterinary medicine used to treat parasite infection, in murine models infected with L. amazonensis. The results from a number of parameters (IgG levels, vacuolar area, megakaryocyte count in spleen and parasite burden) demonstrate that imidocarb has the most potential as a therapy for CL (Rodrigues et al., 2006).

**Antibacterials**

The activity and safety profile of fexinidazole sparked the search for other nitroimidazoles, which
may have potential as oral treatments for VL. This identified the antituberculosis drugs PA-824 (33–34) and delamanid 35, which can also undergo bioactivation by a nitroreductase, as potential leads (Patterson et al. 2013; Gupta et al. 2015; Patterson et al. 2016; Thompson et al. 2016). As with fexinidazole 30 the presence of the nitro group has been shown to be essential for antileishmanial activity (Patterson et al. 2013, 2016). However the nitroreductase found in Mycobacterium tuberculosis [deazafavlin (F420)-dependent nitroreductase (Ddn)] (Manjunatha et al. 2009), is absent in Leishmania and over-expression of the leishmanial nitroreductase did not provide enhanced sensitivity to the drugs, suggesting a different mode of action. This suggests the potential for future combination therapies involving fexinidazole 30 and these antituberculosis drugs. These differences are reinforced by the observation that whilst the (S)-enantiomer of PA-824 33 is currently in phase II clinical trials for tuberculosis it is the (R)-enantiomer of PA-824 34, which shows superior activity against L. donovani parasites, both in vitro and in vivo, with a twice daily dose of (R)-PA-824 34 at 100 mg kg⁻¹ effectively curing a murine model of infection, suppressing infection by 99-9% (Patterson et al. 2013). More recently, the structurally similar compound delamanid 35 (R-enantiomer) has been demonstrated to display high activity in vitro against intracellular L. donovani amastigotes. In addition, a twice-daily oral dose of this nitroimidazole at 30 mg kg⁻¹ for 5 days cured the mice infected with L. donovani (Patterson et al. 2016). Whilst these compounds appear to show considerable potential, a cautionary note arises from the history of the chimeric nitroimidazole, DNDI-VL-2098 36. This compound, following promising early results, was at the final stages of preclinical development for the treatment of VL. However, results from animal models showed a link between dose, length of treatment and testicular toxicity leading to a decision to halt progression (DNDi, 2015). Whether this is a compound specific effect or a class problem remains to be established.

**Antivirals**

Tucaresol 36 is an investigational drug that has completed phase 2 clinical trials as a treatment for HIV (Gori et al. 2004; ClinicalTrials.gov, 2008) and, like the antiparasitic drug Levamisole 31, is an immunomodulator that demonstrates antileishmanial activity in vivo. This novel immunomodulator was inactive in L. donovani intracellular amastigote assays but showed a reduction in parasite burden in mice infected with L. donovani. Tucaresol 36 could be delivered orally at an optimum dose of 5 mg kg⁻¹ to produce a 44 to 62% suppression of liver amastigotes (Smith et al. 2000).

Another drug with immunomodulatory effects being studied as a therapy for leishmaniasis is imiquimod 37. This immune-response modifier is a treatment for gentil warts caused by human papillomaviruses and works through activation of immune cells, including macrophages. Macrophages are the host cells of Leishmania and therefore in 1999 a study was conducted to determine if imiquimod 37 could be used as potential therapy for leishmania. *In vitro* results determined that imiquimod 37 alone was ineffective at treating CL (Seeberger et al. 2003). In 2005, a study focused on new approaches such as combination therapies and conducted a clinical trial of parental antimonial plus topical imiquimod 37 to treat patients with CL. Results from this study showed that 72% of patients treated with the combination containing 37 achieved a cure at 3 months vs 35% treated with the vehicle cream. In addition, accelerated healing and less prominent scarring was observed in the group treated with antimonial and imiquimod 37 compared with therapy with antimonial alone demonstrating that the next clinically available treatment for leishmaniasis might not rely on one but a combination of drugs (Miranda-Verástegui et al. 2005).

**Antihistamines**

Antiallergic compounds, such as quercetin found in Kalanchoe plant extracts, display potent antileishmanial effects. This reflects a capacity to restore the Th1/Th2T cell balance and also to inhibit mast cell histamine release (Cruz et al. 2008, 2012; Muzitano et al. 2008; Gomes et al. 2009; Mlcek et al. 2016). Consistent with these observations, a set of seven H1-antagonists were reported to display activity against *L. infantum* promastigotes with IC₅₀ values in the range 13–84 µM (Pinto et al. 2014). The activity recorded for cinnarizine 38 (Fig. 9, Table 1) was particularly noteworthy as, unlike the other compounds tested, it also demonstrated potency against intracellular amastigotes (EC₅₀ = 21 µM and NCTC cells EC₅₀ = 87 µM). Whilst, initial *in vivo* experiments using hamsters infected with *L. infantum* revealed a lack of efficacy, a liposomal formulation circumvented this problem and enabled effective treatment of infection
in the liver but not the spleen, which could be ascribed to the higher parasite burden (amastigotes/gram of organ) in this latter organ. Cinnarizine 38 has also been described as a calcium channel blocker, which is significant because Reimão et al. (2010) demonstrated the activity of eight calcium channel blockers against intracellular L. infantum amastigotes (EC_{50} = 5–176 µM) (Reimão et al. 2010). Further development of cinnarizine 38 will require the synthesis of more active analogues, an approach challenged by the fact that no target has yet been identified (Pinto et al. 2014).

In a separate study we have successfully developed an enzyme assay to explore the potential of the Leishmania sphingolipid synthase as a new antileishmanial drug target (Mina et al. 2010, 2011). This assay was employed to screen a set of 1040 pharmacologically active compounds selected from the National Institute of Neurological Disorders and Stroke (NINDS). Many of the most active and selective hits have reported antihistamine activity. As these maintained activity in infected cell models they have considerable potential for repurposing as target specific antileishmanials (Brown et al. in preparation).

Central nervous system (CNS) active drugs

Benzodiazepines are sedatives used to treat anxiety, insomnia and seizures and various analogues have been reported to show activity against visceral and CL (Fig. 10). Compound 39, structurally related to pellalone, demonstrated efficacy against L. donovani amastigotes with no observed toxicity (Clark et al. 2007). In a separate study, benzoazepine 40 was effective against L. mexicana promastigotes with a better IC_{50} value than that observed for miltefosine 8 (Navin et al. 2017). However, metabolic studies using rat hepatocytes and microsomal preparation showed that the potential of these compounds is limited by extensive and rapid metabolism. Therefore, further rounds of medicinal chemistry optimisation will be required (Thi et al. 2009).

Tricyclic heterocycles are part of numerous therapeutic agents and therefore important structures in medicinal chemistry (Marcu et al. 2016). Chlorpromazine 41 is perhaps the best known of the phenothiazine drugs (tricyclic heterocycles) for treatment of neurological disorders. In 1984 this compound was identified as having activity against L. donovani in vitro and in vivo (Pearson et al. 1984) and in a separate study also showed it could kill L. mexicana, L. aethiopica and L. major promastigotes at a concentration of 7.5 µg mL^{-1} (El-On et al. 1986). The same study determined the in vivo effect for chlorpromazine 41 in a murine model infected with L. major and L. mexicana and demonstrated leishmanicidal effect in the spleen but not in the skin lesion (El-On et al. 1986). Therefore, like pentamidine, this compound was shown to be effective against VL but with only partial effect against the cutaneous form. Chlorpromazine 41 will probably not be useful in the treatment of VL due to toxicity concerns but these results have led to the investigation of structurally similar compounds (Chan et al. 1998; Mukherjee et al. 2012; Marcu et al. 2016) to explore the SAR. For example, chlorpromazine analogues with a quaternary nitrogen atom 42 have demonstrated antileishmanial, antitrypanosomal and antimalarial activity (Khan et al. 2000; Parveen et al. 2005). These analogues are trypamoethione reductase inhibitors, which are likely to affect the redox defense of the parasite and hence increase the parasites sensitivity to redox-damaged-based drugs. In addition, the enzyme, trypanothione reductase, is present in Leishmania and Trypanosoma but not the mammalian hosts providing the opportunity to design a selective inhibitor (Khan et al. 2000; Parveen et al. 2005).

HTS against the L. major inositol phosphorylceramide synthase (IPCS) formatted into a cell-based yeast assay identified a class of benzazepanes as potent inhibitors of the enzyme with good activity against both L. major and intramacrophage L. donovani with good levels of selectivity vs Human TIP-1 cells; on target effects were shown by comparison with a mutant L. major strain with redundant sphingolipid synthase activity. However, again further progression requires improvements to the pharmacokinetic profile of these compounds (Norcliffe et al., in prep).

The opioid receptor antagonist naloxonazine 43 was identified in a screen comparing promastigote and amastigote activity in which it was uniquely the only compound identified that showed activity against the intracellular amastigote and not the promastigote. Curiously, the structurally related opioid naloxone (Narcan®) was completely inactive against both parasitic forms. Since homologs of opioid receptors have not been identified in the Leishmania genome it is possible that opioids are involved in modulation of host resistance to parasite infection. In support of this, Loperamide 44, a µ-
opioid receptor agonist, was also identified in this study as inhibiting parasite growth with greater activity against the intracellular stage of the parasite (De Muylder et al. 2011).

Finally, antileishmanial activity was observed when the broad spectrum antidepressants, ketanserin 45 and mianserin 46, were screened against L. donovani promastigotes and intramacrophage amastigotes. Amongst other enzymes these compounds are known to target 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR). This is the rate-limiting enzyme of the sterol biosynthesis, which is also the putative pathway targeted by amphotericin B 5. In support of this proposal both compounds inhibited recombinant L. donovani HMGR, although given the diverse reported activities, other modes of action cannot be discounted (Dinesh et al. 2014; Singh et al. 2014b).

Other drugs

Similar to ketanserin 45 and mianserin 46 discussed above, statins target HMGR. Statins are currently on the market to reduce cardiovascular disease by lowering the level of low-density lipoprotein cholesterol (‘bad cholesterol’) in the blood. Studies have shown that statins also have the potential to be repurposed as antileishmanials (Kumar et al. 2016; Parihar et al. 2016). For example, mevastatin 47 also inhibits recombinant L. donovani HMGR enzyme with an IC$_{50}$ value of 42.2 ± 3.0 µM. It also shows correspondingly good activity against both L. donovani promastigotes and intracellular amastigotes with no toxicity exhibited towards the host cell line (Dinesh et al. 2015).

Amiodarone 48 and dronedarone 49, (Fig. 11) used to treat cardiac arrhythmias, have antileishmanial activity against L. mexicana promastigotes and intramacrophage amastigotes, and inhibit oxidosqualene cyclase (OSC), another enzyme essential for ergosterol biosynthesis. However, as with the antihistamines discussed above, these drugs are also known to disrupt Ca$^{2+}$ homeostasis in Saccharomyces cerevisiae and Trypanosoma cruzi, so may have multiple modes of action (Serrano-Martin et al. 2009a). The in vivo activity of amiodarone 48 was investigated in a murine model infected with L. mexicana. amiodarone 48 was given as an

Fig. 10. CNS drugs that could be repurposed as antileishmanials.
oral therapy at 50 mg kg$^{-1}$ day$^{-1}$ and although preventing the development of lesions during the course of treatment, reoccurrences of the infection were observed once treatment had ended. Amiodarone 48 was then tested in combination with miltefosine 8 at a dose of 50 and 20 mg kg$^{-1}$ day$^{-1}$ respectively, and showed permanent control of lesion size. Hence, using this drug in combination with currently available antiparasitics could lower the dosage and reduce the known side effects of amiodarone (e.g. cardiotoxicity, thyroid dysfunction and pulmonary fibrosis) (Serrano-Martín et al. 2009b). Zoxamide 51 killed the promastigotes with an IC$_{50}$ value of 250 nM (Witschel et al. 2012). Although explored in other contexts (Andrews et al. 2014), there has been little reported effort to repurpose veterinary medicines for leishmaniasis, possibly due to the potential human toxicity issues which could arise and negate the benefits of the repurposing approach.

Concluding remarks

The repositioning of old drugs for new uses is not a new concept and is a particularly attractive approach for neglected tropical diseases. Here the use of approved drugs is particularly beneficial as clinical trials have already successfully been conducted and often their patents have expired leading to shorter, cheaper discovery pipelines. As discussed in the various sections above, a wide range of structures have been explored for antileishmanial activity. Significantly, most of the medicines used to treat leishmaniasis, both on the market or under development in the drug discovery process, were initially intended for other indications. Furthermore, more novel approaches show drug repositioning is extending beyond the scope of human medication as investigation into the human use of agrochemicals and veterinary therapeutics is underway. However, drug repurposing is limited by the number of approved drugs and compounds with established pharmacokinetic data, in addition the repositioning discovery process tends to mean that there is less chance of finding treatments that act through a new mechanism of action. Overall, whilst not the sole solution, drug repositioning represents a valuable, relatively fast and cost-effective, strategy for developing essential new therapies, particularly for neglected tropical diseases such as leishmaniasis.
Table 1. List of drugs in this review and their activities

<table>
<thead>
<tr>
<th>Drug</th>
<th>Species</th>
<th>In vitro form</th>
<th>EC_{50} (μM)</th>
<th>Selectivity index</th>
<th>Animal study</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>L. major</td>
<td>Promastigotes</td>
<td>0·11</td>
<td>N</td>
<td></td>
<td>Y</td>
<td>Diaz-Gonzalez et al. (2011)</td>
</tr>
<tr>
<td>L. donovani</td>
<td>Promastigotes</td>
<td>0·14</td>
<td>N</td>
<td></td>
<td>N</td>
<td></td>
</tr>
<tr>
<td>L. major</td>
<td>Promastigotes</td>
<td>0·07</td>
<td>0·08</td>
<td></td>
<td>N</td>
<td>Patel et al. (2014)</td>
</tr>
<tr>
<td>L. donovani</td>
<td>Intracellular amastigotes</td>
<td>1·08 7·04</td>
<td>Y</td>
<td>Sanderson et al. (2014)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>L. mexicana</td>
<td>Intracellular amastigotes</td>
<td>2·63 2·89</td>
<td>N</td>
<td></td>
<td>N</td>
<td></td>
</tr>
<tr>
<td>L. amazonensis</td>
<td>Intracellular amastigotes</td>
<td>3·73 1·88</td>
<td>Y</td>
<td></td>
<td>N</td>
<td></td>
</tr>
<tr>
<td>L. mexicana</td>
<td>Intracellular amastigotes</td>
<td>6·87 1·02</td>
<td>N</td>
<td></td>
<td>N</td>
<td></td>
</tr>
<tr>
<td>L. mexicana</td>
<td>Intracellular amastigotes</td>
<td>4·72 1·48</td>
<td>N</td>
<td></td>
<td>N</td>
<td></td>
</tr>
<tr>
<td>L. major</td>
<td>Intracellular amastigotes</td>
<td>3·77 1·86</td>
<td>N</td>
<td></td>
<td>N</td>
<td></td>
</tr>
<tr>
<td>L. donovani</td>
<td>Intracellular amastigotes</td>
<td>2·49 2·41</td>
<td>Y</td>
<td></td>
<td>N</td>
<td></td>
</tr>
<tr>
<td>L. amazonensis</td>
<td>–</td>
<td>–</td>
<td>Y</td>
<td>Wetzel et al. (2012)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>L. donovani</td>
<td>Axenic amastigotes</td>
<td>0·47 10</td>
<td>N</td>
<td></td>
<td>Y</td>
<td>Wang et al. (2015)</td>
</tr>
<tr>
<td>L. amazonensis</td>
<td>Promastigotes</td>
<td>13·51 1·77</td>
<td>Y</td>
<td>Trinconi et al. (2016)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>L. donovani</td>
<td>Promastigotes</td>
<td>2·49</td>
<td>N</td>
<td></td>
<td>N</td>
<td></td>
</tr>
<tr>
<td>L. amazonensis</td>
<td>–</td>
<td>–</td>
<td>Y</td>
<td>Wetzel et al. (2012)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>L. donovani</td>
<td>Promastigotes</td>
<td>0·47</td>
<td>10</td>
<td>N</td>
<td>Y</td>
<td>Trinconi et al. (2016)</td>
</tr>
<tr>
<td>L. amazonensis</td>
<td>–</td>
<td>–</td>
<td>Y</td>
<td>Mayrhofer et al. (2009)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>L. donovani</td>
<td>Intracellular amastigotes</td>
<td>2·49 2·41</td>
<td>Y</td>
<td></td>
<td>N</td>
<td></td>
</tr>
<tr>
<td>L. major</td>
<td>Intracellular amastigotes</td>
<td>0·015 &gt;407</td>
<td>N</td>
<td>Khraiwesh et al. (2016)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>L. donovani</td>
<td>Promastigotes</td>
<td>0·16</td>
<td>&gt;54</td>
<td>N</td>
<td>Y</td>
<td>Patterson et al. (2013)</td>
</tr>
<tr>
<td>L. donovani</td>
<td>Promastigotes</td>
<td>0·016</td>
<td>&gt;3125</td>
<td>N</td>
<td>Y</td>
<td>Patterson et al. (2016)</td>
</tr>
<tr>
<td>L. donovani</td>
<td>Promastigotes</td>
<td>&gt;50</td>
<td>9·68</td>
<td>N</td>
<td>De Muylder et al. (2011)</td>
<td></td>
</tr>
<tr>
<td>L. donovani</td>
<td>Promastigotes</td>
<td>&gt;50</td>
<td>3·45</td>
<td>N</td>
<td>De Muylder et al. (2011)</td>
<td></td>
</tr>
<tr>
<td>L. donovani</td>
<td>Promastigotes</td>
<td>17·30</td>
<td>3·02</td>
<td>N</td>
<td>De Muylder et al. (2011)</td>
<td></td>
</tr>
</tbody>
</table>
Table 1. Cont.)

<table>
<thead>
<tr>
<th>Drug</th>
<th>Species</th>
<th>In vitro form</th>
<th>EC50 (μM)</th>
<th>Selectivity</th>
<th>Animal study</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>45</td>
<td>L. donovani</td>
<td>Promastigotes</td>
<td>37</td>
<td>3·51</td>
<td>N</td>
<td>Singh et al. (2014)</td>
</tr>
<tr>
<td>46</td>
<td>L. donovani</td>
<td>Intracellular amastigotes</td>
<td>28</td>
<td>2·16</td>
<td>N</td>
<td>Dinesh et al. (2014)</td>
</tr>
<tr>
<td>47</td>
<td>L. donovani</td>
<td>Promastigotes</td>
<td>46</td>
<td>&gt;13</td>
<td>N</td>
<td>Dinesh et al. (2015)</td>
</tr>
<tr>
<td>48</td>
<td>L. mexicana</td>
<td>Promastigotes</td>
<td>0·9</td>
<td>–</td>
<td>Y</td>
<td>Serrano-Martin et al. (2009b)</td>
</tr>
<tr>
<td>49</td>
<td>L. mexicana</td>
<td>Intracellular amastigotes</td>
<td>0·008</td>
<td>–</td>
<td>N</td>
<td>Benaim et al. (2014)</td>
</tr>
<tr>
<td>50</td>
<td>L. major</td>
<td>Promastigotes</td>
<td>0·41</td>
<td>1</td>
<td>N</td>
<td>Firdessa et al. (2015)</td>
</tr>
<tr>
<td>51</td>
<td>L. donovani</td>
<td>Promastigotes</td>
<td>0·25</td>
<td>–</td>
<td>N</td>
<td>Witschel et al. (2012)</td>
</tr>
</tbody>
</table>

FInancial Support

We thank CNPq (PVE Grant: 400894/2014-9 to BRB and PGS); The Royal Society (The Royal Society International Collaboration Awards for Research Professors 2016: IC160044 to BRB and PGS); and BBSC (BB/M024156/1 to PWJ) for financial support.

References


repressing as a strategy for the discovery of new anti-leishmanials

235


